



ANIMA BIOTECH TO PRESENT AT THE BIO CEO & INVESTOR CONFERENCE

BERNARDSVILLE, New Jersey, Feb. 6, 2020 – Anima Biotech, the leader in the discovery of small molecule drugs that control mRNA translation, today announced the company will present at the 22nd Annual BIO CEO & Investor Conference, taking place in New York, Feb. 10 – 11, 2020.

Yochi Slonim, Co-founder and Chief Executive Officer of Anima Biotech, will provide an overview of the company's business, technology and partnering activities and will be available for questions and one-on-one meetings with attendees registered for the conference.

Details regarding the company's presentation are as follows:

Event: 22nd Annual BIO CEO & Investor Conference

Date: Monday, Feb. 10, 2020

Time: 11 a.m. EST

Floor: Fourth Floor

Room: Brecht

Venue: New York Marriott Marquis, 1535 Broadway, New York

About Anima Biotech

Anima Biotech is advancing its Translation Control Platform, the first and only platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against many diseases. With novel biology that monitors the translation of proteins and proprietary cloud-based analysis software, we identify drug candidates that modulate a target protein's production. We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our \$1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations. To learn more about us, visit <https://www.animabiotech.com>

###

Media Contact:

Andrew Mielach

LifeSci Communications

+1.646.876.5868

amielach@lifescicomms.com